{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T23:35:15Z","timestamp":1788305715511,"version":"build-2803163510"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017098","name":"University of California Berkeley Institute for Research on Labor and Employment","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008884","name":"Nakatani Foundation for Advancement of Measuring Technologies in Biomedical Engineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003348","name":"Fukuda Foundation for Medical Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003348","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.atherosclerosis.2026.120684","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T20:30:27Z","timestamp":1774297827000},"page":"120684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Achieving LDL-C &lt;1.0\u00a0mmol\/L and cardiovascular outcomes in patients with coronary artery disease who received percutaneous coronary intervention"],"prefix":"10.1016","volume":"415","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6307-5593","authenticated-orcid":false,"given":"Yu","family":"Kataoka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kitahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Katasako-Yabumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayato","family":"Hosoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Funabashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Mitsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamasa","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Sawada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Matama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Fujino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Yoneda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiyuki","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhide","family":"Asaumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruo","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2026.120684_bib1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib2","first-page":"ehaf190","article-title":"2025 focused update of the 2019 ESC\/EAS guidelines for the management of dyslipidaemias","author":"Mach","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib3","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib4","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib5","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1016\/j.jacc.2018.09.052","article-title":"Medical therapy for long-term prevention of atherothrombosis following an acute coronary syndrome: JACC state-of-the-art review","volume":"72","author":"Gallone","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jacc.2022.08.814","article-title":"Chronic myocardial ischemic syndromes task force. Evolving management paradigm for stable ischemic heart disease patients: JACC review topic of the week","volume":"81","author":"Boden","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib7","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib8","doi-asserted-by":"crossref","first-page":"846","DOI":"10.5551\/jat.GL2017","article-title":"Japan atherosclerosis society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017","volume":"25","author":"Kinoshita","year":"2018","journal-title":"J Atherosclerosis Thromb"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib9","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","article-title":"2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes","volume":"41","author":"Knuuti","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib10","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1253\/circj.CJ-21-1041","article-title":"JCS 2022 guideline focused update on diagnosis and treatment in patients with stable coronary artery disease","volume":"86","author":"Nakano","year":"2022","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib11","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jacc.2011.09.077","article-title":"Functional measurement of coronary stenosis","volume":"59","author":"Pijls","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib12","first-page":"e18","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1253\/circj.CJ-19-1131","article-title":"JCS 2018 guideline on diagnosis of chronic coronary heart diseases","volume":"85","author":"Yamagishi","year":"2021","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib15","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib16","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/CIRCULATIONAHA.122.063399","article-title":"Association between achieved low-density lipoprotein cholesterol levels and long-term cardiovascular and safety outcomes: an analysis of FOURIER-OLE","volume":"147","author":"Gaba","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib17","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib18","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1016\/j.jcmg.2022.03.002","article-title":"Effect of evolocumab on coronary plaque phenotype and burden in statin-treated patients following myocardial infarction","volume":"15","author":"Nicholls","year":"2022","journal-title":"JACC, Cardiovasc Imaging"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib19","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Effect of alirocumab added to high-intensity Statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib20","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2010.02.026","article-title":"Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome","volume":"55","author":"Nicholls","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib21","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1093\/eurheartj\/ehz520","article-title":"Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study","volume":"41","author":"Prati","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib22","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/S0140-6736(19)31794-5","article-title":"Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study","volume":"394","author":"Waksman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib23","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(21)00249-X","article-title":"Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study","volume":"397","author":"Erlinge","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib24","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"DA VINCI study. EU-Wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib25","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib26","doi-asserted-by":"crossref","first-page":"zwaf388","DOI":"10.1093\/eurjpc\/zwaf388","article-title":"International patterns in lipid management and implications for patients with coronary heart disease: results from the INTERASPIRE study","volume":"12","author":"Brandts","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib27","doi-asserted-by":"crossref","first-page":"577","DOI":"10.33963\/v.phj.103434","article-title":"Implementation of cardiovascular prevention guidelines in clinical practice. Results from the POLASPIRE II survey","volume":"83","author":"Jankowski","year":"2025","journal-title":"Kardiol Pol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib28","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/2047487315585293","article-title":"Time trends and gender differences in prevention guideline adherence and outcome after myocardial infarction: data from the SWEDEHEART registry","volume":"23","author":"Hambraeus","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.118.005562","article-title":"Sex differences in the use of statins in community practice","volume":"12","author":"Nanna","year":"2019","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib30","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/0021-9150(80)90184-7","article-title":"Serum lipids and lipoprotein concentrations during the acute phase of myocardial infarction","volume":"35","author":"Heldenberg","year":"1980","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib31","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib32","article-title":"Optimal implementation of the 2019 ESC\/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study","volume":"31","author":"Brandts","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib33","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jacc.2023.02.018","article-title":"Phase 2b randomized trial of the oral PCSK9 inhibitor MK-0616","volume":"81","author":"Ballantyne","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib34","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2025.03.499","article-title":"An oral PCSK9 Inhibitor for treatment of hypercholesterolemia: the PURSUIT randomized trial","volume":"85","author":"Koren","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib35","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMoa2415820","article-title":"Safety and efficacy of obicetrapib in patients at high cardiovascular risk","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.70010","article-title":"Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: an integrated summary of results from non-human primate studies and clinical trials","volume":"12","author":"Nicholls","year":"2024","journal-title":"Pharmacol Res Perspect"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib37","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/jamacardio.2023.5155","article-title":"Impact of bempedoic acid on total cardiovascular events: a prespecified analysis of the CLEAR outcomes randomized clinical trial","volume":"9","author":"Nicholls","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib39","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","article-title":"JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome","volume":"83","author":"Kimura","year":"2019","journal-title":"Circ J"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib40","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","article-title":"Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications","volume":"62","author":"Martin","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib41","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jacl.2017.05.005","article-title":"Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg\/dL compared with a novel low-density lipoprotein estimation method","volume":"11","author":"Whelton","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.atherosclerosis.2026.120684_bib42","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/clinchem\/48.2.236","article-title":"Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation","volume":"48","author":"Nauck","year":"2002","journal-title":"Clin Chem"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502600050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191502600050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:35:06Z","timestamp":1779251706000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191502600050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"alternative-id":["S002191502600050X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120684","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Achieving LDL-C <1.0\u00a0mmol\/L and cardiovascular outcomes in patients with coronary artery disease who received percutaneous coronary intervention","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2026.120684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120684"}}